Trump Eyes Massive Drug Tariffs as Pressure Mounts on Pharma Giants

With input from CNBC, CNN, and Reuters.

The Trump administration is preparing a sharp escalation in its fight with Big Pharma – and this time, the lever is tariffs.

According to a draft proposal, the White House is weighing duties of up to 100% on imported branded drugs and their key ingredients. The target is clear: pharmaceutical companies that haven’t agreed to lower their US prices under the administration’s terms.

The plan isn’t finalized yet. It could still shift, and timing remains uncertain. But insiders suggest an announcement could come quickly, possibly within days. Even in draft form, the message is already landing across the industry.

Cut prices – or pay up.

At the center of the strategy is Trump’s “most favored nation” policy, a framework that ties US drug prices to lower prices abroad. Since late last year, more than a dozen major drugmakers – including Eli Lilly, Pfizer, and Novo Nordisk – have signed on to deals with the administration. Those agreements buy them breathing room: a three-year exemption from tariffs.

Everyone else is now in the crosshairs.

Under the proposal, companies that refuse to cooperate could see their patented drugs hit with a 100% import tariff. That’s a staggering figure in an industry built on global supply chains and carefully balanced pricing models. It would immediately raise costs for firms that rely on overseas production – and force tough decisions about pricing, manufacturing, and market access.

There’s an off-ramp, but it comes with strings attached.

Drugmakers willing to shift production to the United States could face a reduced tariff of around 20% – at least initially. That lower rate would only last for a limited window, reportedly four years, before climbing back to the full 100%. The idea is to push companies not just to commit to US manufacturing, but to do it quickly.

Negotiating with the administration is another way out. Companies already in talks with the Department of Health and Human Services could avoid the tariffs altogether, even if a final deal isn’t signed yet. That detail matters. It creates urgency, but also gives firms a reason to stay at the table.

Not every drug is caught in the net.

Generic medications – often the cheaper alternatives that dominate everyday prescriptions – would be spared from additional tariffs under the current draft. That carve-out helps limit the immediate impact on consumers, at least on paper. Still, branded drugs drive much of the industry’s revenue, and that’s where the pressure is now concentrated.

The broader move fits into a familiar pattern.

Trump has been steadily rebuilding his trade playbook after a major setback earlier this year, when the Supreme Court struck down a sweeping set of tariffs imposed in 2025. Pharmaceuticals had largely escaped those earlier measures. That exemption now looks temporary.

This new approach leans on a different justification: national security.

A Commerce Department investigation recently concluded that certain pharmaceutical imports could pose risks to the United States, particularly given how much of the supply chain sits overseas. That finding gives the administration legal and political cover to act more aggressively.

Behind the scenes, the pressure campaign has already been working.

Even before this latest tariff threat, drugmakers had started shifting course. The combination of pricing demands and the risk of trade penalties triggered a wave of new US manufacturing commitments. Companies began investing in domestic production capacity, trying to stay ahead of policy changes while maintaining access to the lucrative American market.

Now the stakes are higher.

For firms that haven’t signed deals, the choice is narrowing. Accept lower prices in the US, move production stateside, or absorb a massive tariff hit. None of those options are particularly attractive, especially for companies juggling global pricing strategies and investor expectations.

There’s also a political edge to the move.

Trump has repeatedly framed high drug prices as a failure of both industry and policy. The tariff threat turns that argument into a direct confrontation. It’s not just about lowering costs anymore – it’s about reshaping how and where drugs are made, and who controls the pricing power.

Critics, including some within his own party, worry about the ripple effects. Tariffs have a way of feeding back into the system. Higher import costs can translate into higher prices, even when the policy is designed to do the opposite. The administration is betting that competition, negotiations, and domestic production will offset that risk.

That outcome is far from guaranteed.

For now, the pharmaceutical industry is in wait-and-see mode. The draft order leaves room for adjustments – potential exemptions, different timelines, tweaks to enforcement. But the direction is unmistakable. The White House is ready to use tariffs not just as a trade tool, but as a pricing weapon.

And this time, one of the world’s most powerful industries is squarely in the line of fire.